USD10
BCAX Anteile
Über Bicara TherapeuticsBicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
USD10
BCAX Anteile
Über Bicara TherapeuticsBicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
Statistiken
TRADINGFENSTER
Geschlossen
ÖFFNET AM
27. März at 13:30 GMT+0
MARKTKAPITALISIERUNG
1,01 Mrd. $
ERÖFFNUNGSPREIS
Nicht genügend Daten
TIEF (1 J)
7,80 $
HOCH (1 J)
19,71 $
TIEF (24 STD.)
18,30 $
HOCH (24 STD.)
19,12 $
VOLUMEN (24 STD.)
5,00 $
100 %
Kursverlauf
Time | Price | Change |
|---|---|---|
Heute | Nicht genügend Daten | Nicht genügend Daten |
1 Tag | 18,31 $ | |
1 Woche | 18,60 $ | |
1 Monat | 16,89 $ | |
1 Jahr | 13,40 $ |